Alkem Laboratories Limited (NSE:ALKEM)
5,592.00
-34.00 (-0.60%)
Dec 12, 2025, 11:45 AM IST
Alkem Laboratories Revenue
Alkem Laboratories had revenue of 40.01B INR in the quarter ending September 30, 2025, with 17.17% growth. This brings the company's revenue in the last twelve months to 138.90B, up 9.32% year-over-year. In the fiscal year ending March 31, 2025, Alkem Laboratories had annual revenue of 129.65B with 2.34% growth.
Revenue (ttm)
138.90B
Revenue Growth
+9.32%
P/S Ratio
4.84
Revenue / Employee
7.39M
Employees
18,785
Market Cap
672.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 129.65B | 2.97B | 2.34% |
| Mar 31, 2024 | 126.68B | 10.68B | 9.21% |
| Mar 31, 2023 | 115.99B | 9.65B | 9.08% |
| Mar 31, 2022 | 106.34B | 17.69B | 19.96% |
| Mar 31, 2021 | 88.65B | 5.21B | 6.24% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Biocon | 164.76B |
| Glenmark Pharmaceuticals | 159.97B |
| Mankind Pharma | 135.46B |
Alkem Laboratories News
- 2 days ago - Alkem Laboratories’ Daman facility clears Malta GMP inspection with no critical observations - Business Upturn
- 21 days ago - Top stocks to watch today, November 21: TCS, Godrej Properties, JSW Energy, Hyundai Motor India, Alkem Laboratories and more - Business Upturn
- 21 days ago - Alkem Laboratories launches De Simone formulation probiotic ‘DSS’ in India - Business Upturn
- 25 days ago - Jubilant Foodworks, Voltas & more: Top stocks on brokers' radar today - The Times of India
- 4 weeks ago - Nomura bullish on Alkem Labs as company lifts US growth guidance to double digits - Business Upturn
- 4 weeks ago - Alkem Labs share price: Nomura maintains buy with Rs 6,860 target price, says broad-based growth to continue - Business Upturn
- 4 weeks ago - HSBC raises target price for Alkem Labs following better than expected Q2 results - Business Upturn
- 4 weeks ago - Alkem Laboratories Ltd (BOM:539523) Q2 2026 Earnings Call Highlights: Record Revenue and ... - GuruFocus